Sign Out
EFFECTIVENESS AND SAFETY: As early as 15 to 30 days after the first dose of the vaccine has been administered, a significant number of vaccinated persons may already present specific antibodies. At 60 day (after second dose), more than 65 percent of all vaccinated persons have attained seroconversion, and 15 days after having received the third dose, almost 100 percent of these persons remain completely protected for long periods of time. The most appropriate moment for a booster or reactivation dose after having received the full vaccination protocol has not yet been established with complete accuracy, yet this booster shot should always be administered when specific antibody levels drop below 10 IU/liter or from 1 to 2 years after the third dose. For haemodialysis and other immunocompromised patients, booster dose are recommended in order to ensure an antibody level of ≥10 IU/L. The vaccine's high level of purity and the fact that it has been produced from a recombinant yeast source guarantee the absence of any risk of contamination from infective blood agents or other sources of infection. Various studies show that close to 90 percent of all new-born children from infected mothers, vaccinated immediately after birth, remain protected. It has been proven that this vaccine meets the Hepatitis B prevention requirements established by the World Health Organization (WHO).
This vaccine does not prevent hepatitis caused by other agents different from HBV (as virus A, C and E), but it is considered effective to prevent hepatitis caused by the delta agent.
